Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study.

ABSTRACT:

Background

Despite significant advancements in treatment, patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) continue to face the challenge of drug resistance, highlighting the need to develop new drugs and treatment strategies. Pyrotinib has exhibited notable efficacy in managing HER2-positive MBC, especially in individuals with brain metastasis (BM). However, real-world evidence on the effectiveness of pyrotinib re-treatment remains limited.

Objectives

This study aims to assess the efficacy of pyrotinib re-treatment-including treatment beyond progression (TBP) and rechallenge-in patients with HER2-positive MBC, particularly those with BMs, in a real-world clinical setting.

Design

A retrospective, multicenter, real-w

SUBMITTER: Peng J 

PROVIDER: S-EPMC12575939 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature